Sagimet Biosciences (SGMT) has joined the Russell 3000 and Russell 2000 indexes, effective Monday, as part of the 2026 Russell Indexes reconstitution, the company said on the same day.
The company said it has capital in place to fund its programs through 2028, including a planned phase 3 trial of denifanstat in moderate to severe acne, expected in H2.
Price: 7.20, Change: +0.14, Percent Change: +1.91
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments